MedCity News January 20, 2026
Matthias Kleinz, executive vice president and head of translational sciences investments at UPMC Enterprises, explained why biopharma companies cannot ignore China anymore.
Since 2020, UPMC Enterprises, the innovation, commercialization and venture arm of the $28 billion healthcare provider and insurer based in Pittsburgh, has begun directly investing in life sciences companies. That was a change from before, when the focus was on commercializing UPMC’s (University of Pittsburgh Medical Center) internal research and intellectual property, explained Matthias Kleinz, executive vice president and head of translational sciences investments at UPMC Enterprises, in a recent interview.
Since then, it has invested in several outside companies in the U.S. and the U.K., he said. But now, the organization is looking at ways to leverage...
Today's Sponsors
Today's Sponsor